8-K: Globus Medical Appoints New CEO and CFO Amid Strong Preliminary Q2 Sales Growth

Globus Medical, Inc. announced a leadership transition with Keith Pfeil appointed as the new President and CEO, alongside preliminary second-quarter 2025 sales of approximately $745.3 million, an 18.4% increase year-over-year.

Summary

• Daniel T. Scavilla resigned from his positions as President, Chief Executive Officer, and Board member of Globus Medical, Inc., effective July 18, 2025, to pursue another opportunity.
• Keith W. Pfeil was appointed President and Chief Executive Officer, effective July 18, 2025. Mr. Pfeil previously served as the company's Chief Operating Officer and Chief Financial Officer since February 2024.
• Kyle Kline was appointed Chief Financial Officer, effective July 18, 2025. Mr. Kline previously served as Senior Vice President of Finance since January 2024.
• Preliminary sales for the second quarter ending June 30, 2025, are approximately $745.3 million, representing an 18.4% increase over the second quarter of 2024.
• Base business sales, excluding the contribution from the recently acquired Nevro, Inc., are expected to be approximately $650.8 million, an as-reported increase of 3.3% over the second quarter of 2024.
• On a day-adjusted basis, base business sales increased approximately 4.8% over the prior year quarter.
• The US Spine business grew approximately 7.4% on a day-adjusted basis compared to the prior year quarter, achieving its highest quarterly revenue result since the 2023 merger with NuVasive.
• The company reaffirms its guidance for full-year 2025 revenue to be in the range of $2.80 billion to $2.90 billion.
• The company reaffirms its guidance for non-GAAP fully diluted earnings per share to be in the range of $3.00 to $3.30.
• Keith Pfeil's base salary increased to $490,000, and his target annual non-equity incentive program increased to $900,000, along with a grant of an option to buy 40,000 shares of Class A Common Stock.
• Kyle Kline's base salary will be $345,000 per year, and his target bonus amount for the 2025 fiscal year will be $200,000, along with a grant of an option to buy 20,909 shares of Class A Common Stock.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to robust preliminary Q2 sales, significant growth in key segments like US Spine, and the reaffirmation of full-year guidance. The leadership transition, while involving a CEO departure, is framed positively with internal promotions of experienced executives, suggesting continuity and strategic alignment. The compensation increases for the new CEO and CFO also reflect confidence.

Positives

• Preliminary second quarter 2025 sales of approximately $745.3 million represent a strong 18.4% increase over the second quarter of 2024.
• The company reported a significant improvement in Q2 results over Q1, driven by strong performance in the US Spine business.
• The US Spine business achieved approximately 7.4% growth on a day-adjusted basis, marking its highest quarterly revenue since the 2023 merger with NuVasive.
• Notable sequential improvement was observed in Enabling Technology sales.
• The company reaffirmed its full-year 2025 revenue guidance ($2.80 billion to $2.90 billion) and non-GAAP EPS guidance ($3.00 to $3.30), indicating confidence in future performance.
• The appointment of Keith Pfeil as CEO and Kyle Kline as CFO promotes experienced internal leaders, ensuring continuity and leveraging deep company knowledge.
• Keith Pfeil's prior experience as COO and CFO, including leading the NuVasive acquisition and serving on the integration steering committee, positions him well for the CEO role.

Negatives

• Daniel Scavilla's resignation as President and CEO to 'pursue another opportunity' could be perceived as a negative, despite the company stating it was not due to any disagreement.

Risks

• Risks and costs associated with the integration of the NuVasive and Nevro businesses, and the ability to successfully integrate and achieve anticipated synergies.
• Potential impacts from health epidemics, pandemics, and similar outbreaks.
• Factors that could affect quarterly results.
• Challenges in managing growth and sustaining profitability.
• Uncertainty regarding demand for products.
• Ability to compete successfully, including convincing surgeons to use products and attracting and retaining sales and other personnel.
• Ability to rapidly develop and introduce new products.
• Ability to develop and execute on successful business strategies.
• Ability to comply with laws and regulations that are or may become applicable to businesses.
• Ability to safeguard intellectual property.
• Success in defending legal proceedings brought against the company.
• Trends in the medical device industry.
• General economic conditions.

Future Outlook

The company reaffirms its full-year 2025 revenue guidance of $2.80 billion to $2.90 billion and non-GAAP fully diluted earnings per share guidance of $3.00 to $3.30. Management aims to continue the strong Q2 trend, particularly in US Spine, and to continue converting its Enabling Technologies pipeline to further its strategy of becoming the pre-eminent musculoskeletal technology company.

Management Comments

• "We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization." David C. Paul, Globus Medical Founder and Executive Chairman.
• "Im deeply grateful to David and the Board for this opportunity and want to thank Dan for his mentorship and partnership throughout my journey thus far at Globus. Ive had the opportunity to grow with this team over the past 6 years and I am excited to carry forward our strong culture of purpose, innovation and teamwork that will meaningfully impact the lives of patients as we move ahead." Keith Pfeil, President and Chief Executive Officer.
• "Im thrilled to welcome Kyle Kline to our executive leadership team as the next CFO of Globus. He and I have worked closely together and hes been a valued and trusted partner of mine. The combination of his integrity, passion and knowledge of our business makes him the right choice to lead Globus as its next CFO." Keith Pfeil, President and CEO.
• "Our second quarter results demonstrated a significant improvement over Q1, led by our US Spine business, which grew approximately 7.4 percent on a day-adjusted basis compared to the prior year quarter, as well as notable sequential improvement in Enabling Technology sales." Keith Pfeil, President and CEO.
• "Our US Spine business had strong, consistent momentum throughout Q2, delivering its highest quarterly revenue result since the 2023 merger with NuVasive. Looking ahead, we seek to continue this trend, while continuing to convert our Enabling Technologies pipeline." Keith Pfeil, President and CEO.
• "It has been an honor to lead Globus Medical and be part of this exceptional team. As the Company continues to move forward, I have made the decision to step down to pursue another opportunity. I look forward to watching the Companys continued success as Keith leads Globus into its next chapter and know that he will drive meaningful impact to the Company as it moves ahead. Im proud to have been part of Globus." Dan Scavilla.

Industry Context

The announcement reflects ongoing strategic adjustments within the musculoskeletal technology sector, particularly following significant M&A activities like the NuVasive acquisition. The focus on integrating acquired businesses and leveraging enabling technologies aligns with broader industry trends towards comprehensive solutions and technological advancements in surgical procedures. The leadership changes, promoting internal talent, suggest a focus on continuity and leveraging existing expertise to navigate post-merger integration and drive growth in a competitive market.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Likely positive impact due to strong preliminary sales, reaffirmed guidance, and a smooth internal leadership transition, potentially leading to increased share price.
• Employees: Leadership changes may create some uncertainty but also opportunities for growth under new management. Compensation adjustments for new executives are noted.
• Customers: Continued focus on innovation and becoming a 'pre-eminent musculoskeletal technology company' suggests ongoing commitment to product development and solutions.
• Suppliers: No direct impact mentioned, but continued growth implies stable or increased demand for supplies.
• Creditors: Strong financial performance and reaffirmed guidance indicate a healthy financial position, which is positive for creditors.

Next Steps

• Announce full financial results for the second quarter ended June 30, 2025, after market close on Thursday, August 7, 2025.
• Continue to execute the strategy of becoming the pre-eminent musculoskeletal technology company in the world.
• Continue the strong trend in US Spine business.
• Continue to convert the Enabling Technologies pipeline.

Key Dates

Recommendation

Keywords

Musculoskeletal Technology, Medical Devices, Spine, Orthopedic Trauma, Joint Reconstruction, Biomaterials, Enabling Technologies, Leadership Change, CEO Appointment, CFO Appointment, Earnings Guidance, Sales Results, NuVasive Integration, Nevro Acquisition, Corporate Governance, SEC Filing